BiotechTube
Home/Vertex Pharmaceuticals/Reshma Kewalramani
RK

Reshma Kewalramani

Chief Executive Officer and President

Vertex Pharmaceuticals

Therapeutic Areas

Cystic FibrosisHematologyPainMetabolic DisordersGenetic Diseases

Vertex Pharmaceuticals Pipeline

DrugIndicationPhase
Vanzacaftor/Tezacaftor/DeutivacaftorCystic FibrosisPhase 3
Exagamglogene Autotemcel (CASGEVY)Sickle Cell DiseaseApproved
VX-548Acute PainPhase 3
VX-880 / VP-102Type 1 DiabetesPhase 1/2
VX-407Alpha-1 Antitrypsin DeficiencyPhase 2
VX-670APOL1-Mediated Kidney DiseasePhase 2
VX-522Cystic FibrosisPhase 1/2

Leadership Team at Vertex Pharmaceuticals

CW
Charles W. Wagner, Jr.
Executive Vice President and Chief Financial Officer
DA
David Altshuler
Executive Vice President, Global Research and Chief Scientific Officer
SA
Stuart A. Arbuckle
Executive Vice President and Chief Operating Officer
CB
Carmen Bozic
Executive Vice President, Global Medicines Development and Medical Affairs
SH
Seng H. Cheng
Senior Vice President and Chief Technical Operations Officer
View full Vertex Pharmaceuticals profile